Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025)
Historic Return on Capital Employed for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 0.06%.
- Keros Therapeutics' Return on Capital Employed rose 4800.0% to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year increase of 4800.0%. This contributed to the annual value of 0.45% for FY2024, which is 900.0% up from last year.
- Per Keros Therapeutics' latest filing, its Return on Capital Employed stood at 0.06% for Q3 2025, which was up 4800.0% from 0.0% recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Return on Capital Employed ranged from a high of 0.06% in Q3 2025 and a low of 0.52% during Q4 2023
- Its 5-year average for Return on Capital Employed is 0.31%, with a median of 0.37% in 2022.
- Per our database at Business Quant, Keros Therapeutics' Return on Capital Employed plummeted by -1900bps in 2022 and then soared by 4800bps in 2025.
- Keros Therapeutics' Return on Capital Employed (Quarter) stood at 0.24% in 2021, then plummeted by -79bps to 0.44% in 2022, then dropped by -20bps to 0.52% in 2023, then grew by 30bps to 0.37% in 2024, then soared by 116bps to 0.06% in 2025.
- Its last three reported values are 0.06% in Q3 2025, 0.0% for Q2 2025, and 0.02% during Q1 2025.